Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze PTCT stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate PTCT investment potential.

What is PTCT stock price today?

Get real-time PTCT stock price, historical data, and price charts on Financhill. Track PTCT performance with our advanced analysis tools.

Is PTCT a good investment?

Evaluate PTCT investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy PTCT stock?

To buy PTCT stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of PTCT?

View detailed market capitalization data and company valuation metrics for PTCT on our comprehensive analysis page.

What is the P/E ratio of PTCT?

Use our fundamental analysis tools to view PTCT P/E ratio and compare valuation metrics with industry peers.

What are PTCT earnings?

View PTCT earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

PTC Therapeutics, Inc. 10K Form

Buy

PTCT
PTC Therapeutics, Inc.

Last Price:

$77.84

Seasonality Move:

15.67%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-04-25	10Q	PTCT/PTC Therapeutics, Inc. Quarterly
2023-10-26	10Q	PTCT/PTC Therapeutics, Inc. Quarterly
2023-08-03	10Q	PTCT/PTC Therapeutics, Inc. Quarterly
2023-04-27	10Q	PTCT/PTC Therapeutics, Inc. Quarterly
2022-10-27	10Q	PTCT/PTC Therapeutics, Inc. Quarterly
2022-08-04	10Q	PTCT/PTC Therapeutics, Inc. Quarterly

Receive PTCT News And Ratings

See the #1 stock for the next 7 days that we like better than PTCT

PTCT Financial Statistics

Sales & Book Value

Annual Sales:	$806.8M
Cash Flow:	$-322.5M
Price / Cash Flow:	14.34
Annual Sales:	$-1.95
Price / Book:	0

Profitability

EPS (TTM):	8.55560
Net Income (TTM):	$751.7M
Gross Margin:	$688.6M
Return on Equity:	0%
Return on Assets:	32.71%

PTC Therapeutics, Inc. Earnings Forecast

Key PTC Therapeutics, Inc. Financial Ratios

The Gross Profit Margin over the past 14 years for PTCT is 85.36%.
The Selling, General & Administrative Expenses for PTCT have been equal to 37.30% of Gross Profit Margin.
The Research & Development expenses have been 66.25% of Revenue.
The Net Earning history of PTCT is -45.03% of Total Revenues.
Per Share Earnings over the last 14 years have been positive in 5 years.

PTC Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	PTCT
CUSIP:	69366J
Website:	ptcbio.com

Debt

Debt-to-Equity Ratio:	-2.63
Current Ratio:	2.32
Quick Ratio:	2.2

Price-to-Earnings

Trailing P/E Ratio:	0
Forward P/E Ratio:	0

PTCT Technical Analysis vs Fundamental Analysis

Buy

PTC Therapeutics, Inc. (PTCT) is a Buy

Is PTC Therapeutics, Inc. a Buy or a Sell?

PTC Therapeutics, Inc. stock is rated a Buy

The current PTC Therapeutics, Inc. [PTCT] share price is $77.85. The Score for PTCT is 58, which is 16% above its historic median score of 50, and infers lower risk than normal.